Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
USPs of our CNS APIs
- Firm PSD control to help maintain consistency of manufacturing process.
- Sufficient capacity to meet our customer’s global leadership requirements.
- Reliable KSM suppliers in India with timely deliveries and stringent specifications.
- IP compliant process.
- Well-controlled all the plausible impurities within the specified limit.
- Commercially available starting materials.
- Schemes of starting material evaluated.
- Flexible business models to support registrations.
- Adequate capacity available to supply development quantity in short lead time.
- Free from nitrosamine impurities.
- QBD (Quality by Design) based API development for consistent quality profile.
- Continuous improvement in place to achieve cost and quality excellence.
- Process safety and scalability.
- APIs suitable for global formulation development.
- Fully backward integration process.
- Compliant to all pharmacopeia’s.
- Multiple domestic sources for KSMs available.
- Able to match a wide range of particle size requirements.
Get access to Dr. Reddy's largest CNS API portfolios to support your formulation success
Dr. Reddy’s is one of the leading generic pharmaceutical companies and CNS API suppliers in the development and manufacturing of CNS APIs used in formulations to treat indications in the central nervous system (CNS) therapy area. Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
They can act either as neurotransmitter agonists, such as the opioids, which mimic the action of enkephalin, or they can block receptor function. Receptor antagonism is a common mechanism of action for CNS drugs.
The global central nervous system therapeutic market was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of CNS diseases are expected to increase the treatment rate globally.
Used to treat insomnia (trouble sleeping), anxiety, panic attacks, and seizures. They may also be used to relieve anxiety and tension before surgery. Examples of CNS depressants are benzodiazepines, barbiturates, and certain sleep medicines.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。
Let’s talk API sourcing live at
Tackle sourcing bottlenecks and compliance hurdles